Combined Hyperpolarized 13C Pyruvate MRI and FDG-PET Imaging to Assess Heart Muscle Viability and Metabolism in Ischemic Cardiomyopathy Patients Undergoing Coronary Artery Bypass Surgery

What this Trial Is About

The trial investigates ischemic cardiomyopathy ICM, a condition where blood flow to the heart muscle is reduced, affecting heart function. Researchers aim to validate a new combined imaging approach that examines heart muscle viability and metabolism using multiple advanced techniques. This method is designed to improve understanding of heart disease severity and response to surgical treatment in patients with ICM and to establish baseline data from healthy volunteers. The study uses three main imaging tests Single Photon Emission Computed Tomography Myocardial Perfusion Imaging SPECT MPI, 18F-fluorodeoxyglucose positron emission tomography FDG-PET, and Hyperpolarized Carbon-13 Pyruvate Magnetic Resonance Imaging HP-13C MRI. Healthy volunteers will have one imaging session to set baseline parameters. Patients with advanced ICM scheduled for coronary artery bypass graft CABG surgery will undergo imaging before surgery and again 3 to 6 months after surgery to monitor changes in heart metabolism and viability. Participants will be assessed through these imaging sessions, which will be performed on separate days within a three-month period. The study involves collecting detailed metabolic and viability data to correlate with clinical indicators of heart function. Researchers will evaluate these results to better understand heart muscle metabolism and recovery after surgery, with total participation lasting several months including follow-up imaging.

Hyperpolarized 13C Pyruvate-MRI and FDG-PET in a Single Exam for the Prognosis of Ischemic Cardiomyopathy